Growing clinical evidence indicates that dietary L-arginine supplementation can reduce obesity, decrease arterial blood pressure, resist oxidation and normalize endothelial dysfunction to cause remission of type 2 diabetes. The potential molecular mechanism plays a role in modulating glucose homeostasis, promoting lipolysis, maintaining hormone level, ameliorating insulin resistance, and fetal programing in early stage.
The possible signaling pathway of the beneficial effects of L-arginine likely involves L-arginine-nitric oxide pathway through which cell signal protein can be activated. Accumulating studies have indicated that L-arginine may have potential to prevent and/or relieve type 2 diabetes via restoring insulin sensitivity in-vivo.
In an open-label randomised limited study conducted by the author, 5 g/day l-arginine base was administered orally once at night for 28 days in 21 subjects with age ranging between 41 and 75 years old (14 between 41 and 49 years, 4 between 50 and 59 years, 2 between 60 and 69 years, and 1 between 70 and 79 years), 16 were males and 5 females, 17 were non-smokers and 4 smokers, and 18 of the 21 subjects were taking other medications to control either hypertension, myocardial ischemia, diabetes, gastro-oesophageal reflux disease (GERD) and hyperacidity, hypothyroidism, neuritis, or rheumatoid. All recruited subjects gave written informed consent that complied with the principles of the Helsinki declaration.
A questionnaire was given to the subjects to be completed weekly for 4 weeks. The subjects were advised to write their health status before and after taking l-arginine. The questionnaire included 30 points regarding their mental, muscular, sexual, circulatory, GIT, and other functions during the 4-week administration. Scoring was recorded from 1 to 5; 1 was a remarkable improvement, 2 was a mild improvement, 3 no difference, 4 was worse than before, and 5 was not applicable.
The subjects were also advised to report any adverse reactions developed during the administration of the supplement. In addition, they were asked if they wanted to continue taking the supplement after termination of the study. Tables 4 and 5 summarise the most noteworthy information of this pilot study.
|Feature||% of cases (total = 21 cases)|
|Mental capability||Remarkable improvement||Mild improvement||No change|
|Ability to concentrate||55||35||10|
|Delay in mental exhaustion||75||15||10|
|Reduction in severity of anxiety and stress||60||20||20|
|Reduction in nervousness||72||21||60|
|Deepness of sleep||80||10||10|
|Muscular activity||Remarkable improvement||Mild improvement||No change|
|Delay in muscular exhaustion||60||15||25|
|Sexual performance in males||54||33||13|
|Overall feeling of well being||65||20||15|
Table 5. Additional observations at the end of the 4-week study reported by some subjects.
At the end of the study, none of the 21 cases experienced any side effects or aggravation of health problems from l-arginine administration. All the 21 cases wanted to continue taking the supplement after termination of the study. Source
Further evidence shows anti-aging effects of L-arginine on a cellular level, meaning that every aspect of physiological function is positively impacted by the presence of NO (Nitric Oxide) and all there is ample scientific evidence to support this and many other claims related to this effect, far beyond the scope of what we can discuss here.